Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Century Therapeutics Inc
(NQ:
IPSC
)
2.020
+0.230 (+12.85%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
567,173
Open
1.820
Bid (Size)
2.020 (2)
Ask (Size)
2.200 (45)
Prev. Close
1.790
Today's Range
1.810 - 2.050
52wk Range
1.280 - 5.510
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Robinhood To Rally Around 29%? Here Are 10 Top Analyst Forecasts For Thursday
August 15, 2024
Via
Benzinga
IPSC Stock Earnings: Century Therapeutics Beats EPS for Q2 2024
August 08, 2024
IPSC stock results show that Century Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Performance
YTD
-44.51%
-44.51%
1 Month
-11.01%
-11.01%
3 Month
-38.79%
-38.79%
6 Month
-45.55%
-45.55%
1 Year
-19.52%
-19.52%
More News
Read More
Century Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates
August 08, 2024
From
Century Therapeutics, Inc.
Via
GlobeNewswire
5 Analysts Assess Century Therapeutics: What You Need To Know
June 04, 2024
Via
Benzinga
Century Therapeutics Presents Interim Results from Phase 1 ELiPSE-1 Study at ASCO 2024 Annual Meeting
June 03, 2024
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Century Therapeutics: Q4 Earnings Insights
March 14, 2024
Via
Benzinga
Century Therapeutics Presents Preclinical Data Highlighting Advances in iPSC Platform Technology and Programs at 2024 ASGCT Annual Meeting
May 10, 2024
From
Century Therapeutics, Inc.
Via
GlobeNewswire
IPSC Stock Earnings: Century Therapeutics Beats EPS, Misses Revenue for Q1 2024
May 09, 2024
Via
InvestorPlace
Century Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
May 09, 2024
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Century Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
April 23, 2024
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Small-Cap Firm Century Therapeutics' Expands into Autoimmune Diseases, Analyst Says Clade Therapeutics Acquisition Intriguing
April 11, 2024
Via
Benzinga
Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics
April 11, 2024
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting
April 08, 2024
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors
March 25, 2024
From
Sagimet Biosciences Inc.
Via
GlobeNewswire
Century Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
March 19, 2024
From
Century Therapeutics, Inc.
Via
GlobeNewswire
IPSC Stock Earnings: Century Therapeutics Misses EPS, Misses Revenue for Q4 2023
March 14, 2024
Via
InvestorPlace
Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business Updates
March 14, 2024
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Century Therapeutics Announces Six Upcoming Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting
March 05, 2024
From
Century Therapeutics, Inc.
Via
GlobeNewswire
3 Millionaire-Maker Under-$10 Stocks to Buy in February 2024
February 22, 2024
Via
InvestorPlace
Century Therapeutics to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
February 01, 2024
From
Century Therapeutics, Inc.
Via
GlobeNewswire
IN8bio's Phase 1 Clinical Trial Of INB-100 Offers Hope To Leukemia Patients With Promising Data
January 22, 2024
Via
Benzinga
Russell 2000 Rallies To 16-Month Highs: Best Performing Small-Cap Stocks Popping Over 80% In December
December 19, 2023
Via
Benzinga
Topics
ETFs
Century Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion™ Edits
December 09, 2023
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Century Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data from Phase 1 ELiPSE-1 trial of CNTY-101 in Relapsed or Refractory B-cell Lymphomas and Planned Phase 1 Study in Systemic Lupus Erythematosus
December 06, 2023
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Century Therapeutics Receives FDA Clearance of IND Application for CNTY-101 in Systemic Lupus Erythematosus
December 06, 2023
From
Century Therapeutics, Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.